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Introduction: Detection of the ALK rearrangement in a solid tumor 
gives these patients the option of crizotinib as an oral form of anti-
cancer treatment. The current test of choice is fluorescence in situ 
hybridization (FISH), but various cheaper and more convenient immu-
nohistochemical (IHC) assays have been proposed as alternatives.
Methods: Fifteen FISH-positive cases from patients, seven with 
data on crizotinib therapy and clinical response, were evaluated 
for the presence of ALK protein using three different commer-
cially available antibodies: D5F3, using the proprietary automated 
system (Ventana), ALK1 (Dako), and 5A4 (Abcam). A further 14 
 FISH-negative and three uncertain (<15% rearrangement detected) 
cases were also retrieved. Of the total 32 specimens, 17 were exci-
sions and 15 were computed tomography-guided biopsies or cyto-
logical specimens. All three antibodies were applied to all cases. 
Antibodies were semiquantitatively scored on intensity, and the pro-
portion of malignant cells stained was documented. Cutoffs were 
set by receiver operating curve analysis for positivity to optimize 
correct classification.
Results: All three IHC assays were 100% specific but sensitivity did 
vary: D5F3 86%, ALK 79%, 5A4 71%. Intensity was the most dis-
criminating measure overall, with a combination of proportion and 
intensity not improving the test. No FISH-negative IHC-positive 
cases were seen. Two FISH-positive cases were negative with all 
three IHC assays. One of these had been treated with crizotinib and 
had failed to show clinical response. The other harbored a second 
driving mutation in the EGFR gene.
Conclusions: IHC with all three antibodies is especially highly spe-
cific (100%) although variably sensitive (71%-86%), specifically in 
cases with scanty material. D5F3 assay was most sensitive in these 
latter cases. Occasional cases are IHC-positive but FISH-negative, 
suggesting either inaccuracy of one assay or occasional tumors with 
ALK rearrangement that do not express high levels of ALK protein.
Key Words: Pulmonary adenocarcinoma, ALK, Immunohisto chemistry, 
Fluorescence in situ hybridization, Crizotinib
(J Thorac Oncol. 2014;9: 769–774)
Rearrangements of the anaplastic lymphoma kinase (ALK) gene drive the malignant phenotype in 3% to 7% of pri-
mary lung adenocarcinomas.1–5 The resulting fusion protein, 
most often a fusion with echinoderm microtubule-associated 
protein-like 4 (ELM4), has a constitutively active tyrosine 
kinase domain. The small molecule drug crizotinib is a spe-
cific inhibitor of this kinase,6 and cases with the rearrange-
ment respond to crizotinib treatment.7 Therefore, accurate, 
rapid, and inexpensive identification of tumors growing under 
the influence of translocated ALK is needed.
Currently the only test approved by the FDA is fluo-
rescence in situ hybridization (FISH) using “break-apart” 
probes (Vysis, Abbott Molecular, Abbott Park, IL). This 
test is regarded as the “gold standard” for detection of 
 re-arrangements and is recommended by CAP/International 
Association for the Study of Lung Cancer/AMP.8 However, 
FISH is technically demanding, expensive, and many diag-
nostic laboratories lack either the expertise or the facilities 
to perform the test. Even in ideal circumstances, the results 
are often difficult to interpret, requiring the scrutiny of large 
numbers of individual cells by a highly experienced diagnos-
tician. Furthermore, there are rare circumstances (such as 
small intrachromosomal inversion) in which the FISH test is 
negative but the tumor nevertheless expresses EML4-ALK 
fusion protein.5,9–11
A cheaper and potentially more widely applicable 
method is immunohistochemistry (IHC); indeed, overex-
pression of ALK protein has been used in the diagnosis of 
anaplastic large-cell lymphoma for many years. Although 
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early studies in lung cancer lacked sensitivity,4,5 more recent 
studies have shown greater specificity and sensitivity,8–11 
and recent international guidelines (CAP/International 
Association for the Study of Lung Cancer/AMP) have rec-
ommended that, if clinically validated, IHC may be used 
as a screening test for FISH testing.8 However, there have 
been few comparative studies on the most appropriate 
antibody to use.
The aim of this study was therefore to compare three 
different immunohistochemical assays, two being routine 
methods using antibodies widely used in the diagnosis of lym-
phoma, with the third being a proprietary system, including 
signal amplification, that is currently being promoted as an 
alternative to FISH (Ventana). We also evaluated the relation-
ships between ALK rearrangement as detected by FISH, IHC, 
and patient response to therapy.
MATERIALS AND METHODS
Clinical Samples
The diagnostic archives from the Royal Brompton and 
Harefield NHS Foundation Trust and Royal Marsden hospi-
tals from 2007 onwards were reviewed to identify cases with 
a diagnosis of lung adenocarcinoma that tested positive for an 
ALK rearrangement (>15% positive cells), and a randomly 
selected complementary group of cases with a normal ALK 
locus for comparison. We had been testing all primary lung 
tumors regardless of stage as part of a feasibility study, which 
led to a large number of early stage cases being included. More 
recently, our current policy is only to test advanced cases of 
non-squamous non–small-cell carcinoma using IHC screening 
with confirmatory FISH as per recently published guidelines.8 
The cases under study are summarized in Table 1.
TABLE 1.  Summary Data of All Cases Included in the Study
Tumor Type Specimen Sex Age Stage
Smoking 
History? ALK FISH TKI
Clinical 
Response
aCa Excision F 61 pT1a(2)/T3N0pM1b Not known Pos Yes Yes
aCa Biopsy F 47 T4 Non-smoker Pos Yes Yes
NSCLC fav aCa Cytology M 35 T4 (pN3) Not known Pos Yes Yes
aCa Cytology F 50 T4B Non-smoker Pos Yes Yes
aCa Cytology F 50 T2N0M1B Non-smoker Pos Yes No
aCa Biopsy F 38 T4B Non-smoker Pos Yes Mixed
aCa Cytology M 35 T4B Non-smoker Pos Yes Yes
Carcinosarcoma Cytology M 77 T4N2M0 Ex-smoker Uncertain No
aCa Biopsy F 78 T4N0M0 Ex-smoker Uncertain No
SCC Biopsy M 64 T4N3M1B Ex-smoker Uncertain No
NSCLC fav aCa Cytology F 73 T1apN3 Non-smoker Pos No
aCa Excision F 66 pT2bN2 Not known Pos No
aCa Excision M 63 pT1aN0 Smoker Pos No
aCa Excision M 54 Recurrence (unknown) Smoker Pos No
aCa Excision M 45 M1b Not known Pos No
NSCLC fav aCa Cytology F 41 pN2 Not known Pos No
aCa Excision F 64 pT1bN0 Non-smoker Pos No
aCa Cytology F 28 TXN0M1A Non-smoker Pos No
SCLC Biopsy M 30 T4B Ex-smoker Neg
aCa Excision M 74 pT1bN0 Not known Neg
NSCLC fav aCa Biopsy F 66 pT2apN0 Not known Neg
aCa Excision M 71 pT1a N0 Ex-smoker Neg
aCa Excision M 79 pT2a N0 Not known Neg
aCa Excision M 63 pT2aN0 Smoker Neg
aCa Biopsy M 61 pT1a N0 Not known Neg
aCa Excision F 54 pT1a NX Non-smoker Neg
aCa Excision F 48 pT1b N0 Smoker Neg
aCa Excision F 66 pT2b N0 Non-smoker Neg
aCa Excision F 82 pT2b N0 Ex-smoker Neg
aCa Excision M 78 pT2a N2 Not known Neg
aCa Excision M 53 pT2a N2 Ex-smoker Neg
aCa Excision M 68 pT1a N0 Smoker Neg
aCa, adenocarcinoma; SCC, sodium citrate; NSCLC, non–small-cell lung cancer; TKI, tyrosine kinase inhibitor treatment (crizotinib); NSCLC fav aCa, NSCLC favoring 
adenocarcinoma on immunohistochemistry; FISH, fluorescence in situ hybridization. 
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Paraffin blocks from a total of 32 diagnostic cases 
were retrieved; 15 of these had tested positive for the ALK 
rearrangement by FISH, three were uncertain (with <15% 
of cells showing rearrangement), and the remaining 14 
cases were negative. All but two blocks dated from 2011 
or later. Seventeen cases were blocks from tumor exci-
sions (six of these were FISH positive) and the remainder 
were cytological or core biopsy/endobronchial ultrasound 
samples.
Data on treatment with crizotinib and response were 
retrieved from patient records. Cases with at least partial 
response to treatment defined according to the Response 
Evaluation Criteria in Solid Tumors criteria12 (i.e., at least 
30% decrease in the sum of the longest diameters of target 
lesions) were designated as “responsive”.
The study was evaluated and classified as a service eval-
uation by the Imperial College Heads of Consortia and as such 
was exempt from Research Ethics Committee review.
Fluorescent In Situ Hybridization
Unstained 2 μm FFPE sections were put through depa-
raffinization and protease pretreatment steps before being 
denatured and hybridized overnight with the commercially 
available Vysis ALK dual color break apart probe (Abbott 
Molecular). Tissue sections then underwent SSC washes and 
were mounted in 4',6-diamidino-2-phenylindole for nuclei 
counterstaining. Results were analyzed and interpreted in 
accordance with probe manufacturer’s instructions.
Non-rearranged ALK showed as fused (yellow) signals. 
Rearranged ALK appeared as split 3′ (red) and 5′ (green) sig-
nals or an isolated 3′ (red) signal. The recommended cutoff of 
15% was used to interpret samples as positive or negative for 
ALK rearrangements in 200 nuclei.
Immunohistochemistry
An additional five sections were cut per case. Three were 
used for the immunohistochemical assays and the remaining 
two for negative controls.
Immunohistochemical assays were optimized using 
the monoclonal antibodies D5F3 (Ventana), ALK1 (Dako) 
and 5A4 (Abcam). The D5F3 assay was performed using 
the Ventana autostainer and a tyramide amplification step, 
as specified in the manufacturer’s protocol. The other assays 
were performed using a Dako autostainer with conventional 
 polymer-based diaminobenzidine staining (no tyramide ampli-
fication). Details of the antibodies and conditions employed 
are given in Table 2.
Scoring
Immunohistochemically stained sections were exam-
ined without knowledge of FISH status by two pathologists 
independently. Scores for proportion and intensity of immu-
nohistochemical staining were assigned by consensus.
The predominant intensity of staining was recorded on 
a scale of 0–3 (0 = negative, 1 = weak, 2 = moderate, 3 = 
strong). As the Ventana stain was more intense, due at least 
partly to the signal amplification step, the visual cutoffs for 
intensity scoring with this antibody were different (e.g., a 
“moderate” degree of intensity seen with the Ventana stain 
would usually be interpreted as “strong” on a section stained 
with 5A4). The proportion of malignant cells staining posi-
tive was recorded as per “Allred” estrogen receptor scoring in 
breast cancer, on a scale of 0–5 (0 = 0%, 1 ≤ 1%, 2 = 1–10%, 
3 = 11–33%, 4 = 34–66% and 5 ≥ 66%). A composite score 
(intensity + proportion) was also derived.
Statistical Analysis
Statistical analyses were performed using the STATA/
IC package.
RESULTS
Fluorescence In Situ Hybridization
Slides were scored according to the manufacturer’s rec-
ommendations. Representative FISH images are shown in 
Figure 1A. The 15 positive cases all showed greater than 15% 
cells with rearranged ALK genes. Three cases were classified 
as “indeterminate”; these were all scanty biopsy or cytologi-
cal samples with 10% to 15% of positively rearranged FISH 
signals. Seventeen further cases were FISH negative.
Immunohistochemistry
No signal was observed in negative controls. The intensity 
of staining between the three antibodies varied (Fig. 1B). IHC 
was impossible to assess in three cases with very scanty mate-
rial (two FISH negative and one FISH positive). The Ventana 
assay using the D5F3 antibody gave the most intense cytoplas-
mic signal, but this was accompanied by higher background 
staining, which was especially noticeable in macrophages. The 
ALK1 and 5A4 antibody assays produced weaker staining but 
with less background. Of the two, 5A4 had marginally more 
background staining, especially in macrophages.
The value of both intensity and proportion scores was 
assessed. Cutoffs for positivity were set using ROC analysis 
to optimize correct classification of ALK status, using FISH 
TABLE 2.  Immunohistochemical Assay Conditions Used
Antibody Supplier Species Antigen Retrieval Dilution Primary Incubation
Tyramide 
Amplification?
D5F3 Ventana Rabbit 92 minutes, 100°C, Cell conditioning 1 1:1 16 minutes, 37°C Yes
ALK1 Dako Mouse 60 minutes, 97°C, high pH TRS 1:20 30 minutes, ambient temp No
5A4 Abcam/Novocastra Mouse 60 minutes, 97°C, low pH TRS 1:50 30 minutes, ambient temp No
The D5F3 assay was performed using the proprietary Ventana immunostaining system. ALK1 and 5A4 assays were performed using a Dako autostainer.
TRS, target retrieval solution (Dako).
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results as the standard (Table 3). The intensity score alone was 
seen to outperform both proportion and the aggregate score. 
Therefore intensity scoring using the optimized cutoff was 
used in subsequent analyses.
Concordance between FISH and IHC is shown in 
Table 4. No cases with negative FISH results and positive 
IHC were identified (100% specificity of IHC in these data). 
Sensitivity was the same (83%) for all three assays in excision 
specimens. In small biopsies and cytological specimens, how-
ever, the D5F3 antibody was the most sensitive. The ALK1 
and 5A4 assays failed to identify a further one or two FISH-
positive cases, respectively. All three assays failed to stain the 
same two cases which contain rearranged ALK genes detect-
able by FISH.
Response to Therapy
Seven cases with ALK rearrangements detected by FISH 
went on to receive crizotinib therapy. All but one showed at 
least a partial response. This crizotinib-refractory case showed 
no detectable ALK expression by all three IHC assays.
FIgURE 1. (A) Representative fluorescence 
in situ hybridization images showing normal 
fused signals (neg) and nuclei with multiple 
separated red signals (pos). (B) Three represen-
tative excision specimens of adenocarcinoma. 
Case 1 is negative with all three immunohisto-
chemical assays; the D5F3 assay shows relatively 
high background, presumably because of the 
tyramide signal amplification (TSA) step. Cases 
2 and 3 are positive with all three immuno-
histochemical assays, with clear cytoplasmic 
staining. The markedly reduced signal seen with 
the 5A4 and ALK1 assays in case 2 was typical 
and again probably related to the absence of 
tyramide amplification. Case 3 demonstrates that 
occasional cases show strong staining using the 
non-TSA assays.
TABLE 3.  Optimised Cutoff Values for Immunohistochemical Tests
Intensity Proportion Combined
Cutoff % Correctly Classified Cutoff % Correctly Classified Cutoff % Correctly Classified
DF3 Ventana >1 93 >4 80 >5 86
ALK1 Dako >1 90 >2 90 >3 90
5A4 Abcam >0 86 >0 86 >0 86
TABLE 4.  Concordance of Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Assays
IHC
FISH
Specificity (%)
Sensitivity (%)
Neg/Indeterminate Pos All cases Excisions Biopsies/Cytology
DF3 Ventana Neg 15 2 100 86 83 88
Pos 0 12
ALK1 Dako Neg 15 3 100 79 83 75
Pos 0 11
5A4 Abcam Neg 15 4 100 71 83 63
Pos 0 10
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DISCUSSION
We have compared three different antibody assays for 
the ALK kinase domain to the current standard FISH assay in 
a set of archival tumors, including 15 FISH-positive cases. We 
found all three assays to be specific (100%) and sensitive (up 
to 86%), especially when a signal amplification technique is 
employed. Furthermore, data on response to crizotinib therapy 
in seven treated cases showed all but one case responded. The 
case that failed to respond to therapy was negative by all three 
IHC assays.
Of the three antibody methods compared, the D5F3 
antibody using a Ventana proprietary assay performed the 
best, especially in scanty samples, which is likely to be a con-
sequence of the tyramide signal amplification step incorpo-
rated into the Ventana assay. It is possible that the other two 
antibodies would perform as well, if a suitable signal amplifi-
cation step were introduced. However, an assay using the 5A4 
without tyramide amplification has been successfully applied 
by To et al in a recent comparable assessment of IHC as a test 
for ALK rearrangement.5 In a set of 373 tumors that included 
20 ALK rearrangements as detected by FISH, their IHC assay 
was 99% specific and 100% sensitive.
In contrast to this, we find 100% specificity and (at 
best) 86% sensitivity; that is to say, we identified rare FISH-
positive IHC-negative cases, whereas To et al found occa-
sional  FISH-negative IHC-positive cases, which were proved 
to harbor EML4-ALK rearrangements by reverse transcrip-
tion polymerase chain reaction (RT-PCR).5 It is unsurprising 
that we do not identify FISH-negative IHC-positive cases as 
we only examined 17 FISH-negative or indeterminate cases in 
comparison to the 356 examined by To et al.5 It is more nota-
ble that To et al.5 do not identify FISH-positive, IHC-negative 
cases. This might be explained by their use of tissue microar-
rays for FISH, which is even more technically demanding and 
hard to interpret than FISH using whole sections.
This possible shortcoming of tissue microarray meth-
ods might be apparent in two other recent studies using tissue 
microarrays for a comparison of FISH with ALK1, 5A4 and 
D5F3 antibodies.13,14 Selinger et al.13 describe 100% sensitivity 
for all three antibody assays. Conklin et al.14 also find 100% 
sensitivity and a maximum specificity of 88% (again using the 
5A4 antibody). Again, it may be that in both these additional 
studies the approach used hampered the identification of FISH-
positive, IHC-negative cases because of the difficulty of apply-
ing FISH to TMAs, especially when the primary test has been 
IHC and the FISH test is not “blind” to the IHC result.
Other recent studies compare various immunohisto-
chemical assays and FISH for the detection of ALK rearrange-
ments.15,16 As in this study, Sholl et al.15 identify occasional 
FISH-positive, IHC-negative cases. They explain two cases by 
identifying co-existent mutations in other driving oncogenes 
(presumably thereby relieving the tumor “addiction” to ALK) 
and one by insufficient tumor material for accurate IHC assess-
ment. Savic et al.16 compared an immunocytochemical assay 
using the 5A4 antibody to FISH in cytological specimens and 
achieved a sensitivity of 93% and specificity of 96%, which is 
comparable with our findings in cytological and small biopsy 
cases (sensitivity 88%, specificity 100%).
In the current study, we detected two “false-negative” 
cases, which were positive by FISH and negative by all three 
IHC assays. This combination has two possible explanations. 
Firstly, they might represent tumors which are not expressing 
ALK protein at detectable levels, because of a false-positive 
FISH result, or an absence of addiction to rearranged ALK 
protein despite presence of recombined ALK DNA. These 
tumors are unlikely to respond to crizotinib. Secondly, they 
might represent a failure of the IHC assay, because of poor 
preservation of antigen, insufficient material or another tech-
nical error. In this case, crizotinib therapy would still be likely 
to be effective.
The study includes seven cases with positive FISH 
results with data on response to crizotinib. Six showed at 
least a partial response to crizotinib therapy, as assessed by 
Response Evaluation Criteria in Solid Tumors criteria. A 
single case showed no response, and this was one of the two 
“false negatives”. Thus, in this one case, the IHC test would 
have correctly predicted response. This was a scanty cytologi-
cal specimen in which FISH interpretation was difficult, and 
only 20% of 515 cells showed rearranged ALK signals (fusion 
plus split red/green probes and fusion plus isolated red sig-
nal). Therefore, it seems possible that this represents a techni-
cal failure of the FISH assay.
The other case, an excision specimen, showed 39% of 
626 cells with rearranged signals. It was also shown to har-
bor a driving mutation in a second gene; PCR testing dem-
onstrated the loss of exon 19 of endothelial growth factor 
receptor. This has been described in another study that charac-
terized two such “false-negative” cases.15 Thus, these tumors 
may well escape “oncogene addiction” to the ALK kinase 
activity, which would be consistent with indetectable ALK 
protein expression. Again, IHC would be expected to be the 
best predictor of response to tyrosine kinase inhibitor therapy 
in such cases.
It is essential to identify and molecularly character-
ize other “false-negative” cases that have received crizotinib 
therapy. In addition, it seems likely that IHC should guide 
treatments in “false-positive” cases that express high levels 
of ALK from genetic lesions that are invisible to the current 
FISH assay.
Although we identified no “false positives”, i.e., 
 FISH-negative, IHC-positive cases, our sensitivity may be an 
overestimate (as judged by FISH) because of the small num-
ber of FISH-negative cases under study. Several studies have 
identified rare cases with rearrangements that are indetectable 
by FISH but detectable by IHC and confirmed by reverse-tran-
scriptase PCR.5,9,10 Such cases would be expected to respond 
to crizotinib, and a recent study shows that at least one novel 
“FISH-indetectable” rearrangement does indeed drive the 
malignant phenotype.5
One limitation of this study is the small number of cases 
under study, although 15 FISH-positive cases is comparable 
to most other studies. The relatively small number of FISH-
negative cases may have affected our ability to identify FISH-
negative, IHC-positive cases. However, the study design does 
permit an assessment of the sensitivity of the IHC assay, which 
is the most important consideration for a possible screening 
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test. Our comparison of the immunohistochemical assays was 
not directly equivalent, as the D5F3 assay included a propri-
etary tyramide signal amplification step, whereas the ALK1 
and 5A4 assays were conducted using our routine diagnostic 
detection system. However, our study design also has several 
strengths. In particular, the use of archival diagnostic paraf-
fin blocks, and FISH testing conducted in the course of rou-
tine diagnosis make the results of the study directly relevant to 
clinical practice.
In summary, we find IHC to be a highly sensitive (86%) 
and specific (100%) test for ALK rearrangement in lung 
adenocarcinoma. We find a slight advantage of a proprietary 
amplified assay (D5F3 Ventana) over two other antibod-
ies with conventional DAB staining (ALK1 Dako and 5A4 
Abcam), but only in scanty samples. Intensity of staining was 
the most discriminating measure, and the proportion of cells 
staining did not contribute. We identified two cases that were 
positive for the ALK rearrangement by FISH but negative by 
all immunohistochemical assays and suggest that in discor-
dant cases the IHC test result may be more predictive of treat-
ment response than FISH. Further discordant cases need to be 
examined to help guide the treatment of these cases.
Immunohistochemical testing is clearly at least a use-
ful adjunct to FISH, and we feel that it is reasonable in rou-
tine practice to use a sensitive IHC assay as a screening test. 
The danger of missing treatable cases using this method (i.e., 
FISH-positive, IHC-negative, crizotinib-sensitive tumors) 
appears very small, especially when specimens contain ade-
quate material. In difficult cases, further investigations such as 
re-biopsy and repeated IHC/FISH may be helpful.
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